Studies support dinutuximab beta in treating neuroblastoma – EUSA Pharma

EUSA Pharma’s studies of Qarziba in treatment of high-risk neuroblastoma support the use of dinutuximab beta as standard-of-care immunotherapy for high-risk neuroblastoma patients.

Professor Ruth Ladenstein, St Anna Children’s Hospital and Department of Pediatrics, Medical University Vienna, Austria, and Principal Investigator of the HR-NBL1/SIOPEN trial, said, “The data to be presented at ASCO, which are based on extensive collaboration between the SIOPEN network, Apeiron Biologics and EUSA Pharma, support the use of dinutuximab beta as standard-of-care immunotherapy for high-risk neuroblastoma patients without the addition of subcutaneous interleukin-2.”

Professor Holger Lode, Chair of Pediatrics and Pediatric Hematology and Oncology, University Medicine Griefswald,Germany, and Principal Investigator of the SIOPEN LTI trial, said: “These new results from the SIOPEN study further support the role of dinutuximab beta in treating children with high-risk relapsed/refractory neuroblastoma, a deadly disease and ultra-orphan indication.”

Lee Morley, EUSA Pharma’s Chief Executive Officer, said: “We are delighted these new data supporting the efficacy and tolerability of QARZIBA (dinutuximab beta) in both the maintenance phase of first-line treatment of high-risk neuroblastoma as well as relapsed/refractory neuroblastoma will be presented at the prestigious ASCO Annual Meeting. With the recent appointment of Darrel Cohen MD PhD as EUSA’s Head of Clinical Development, we are exploring further development of dinutuximab beta in neuroblastoma, and other GD2-expressing oncology indications with high unmet clinical need, as part of our commitment to ensuring patient access to this important medicine globally.”